Evaluation of mouthrinse and dentifrice regimens in an in situ erosion remineralisation model.
OBJECTIVE
To compare the effectiveness of dentifrice/mouthrinse regimens in a clinical in situ erosion remineralisation model.


METHODS
Thirty-six subjects completed a randomised single-blind cross-over trial of five treatment regimens. R1: Dentifrice A [1450 ppm fluoride as the sodium salt (NaF), 50000 ppm potassium nitrate (KNO(3))] plus 450 ppm fluoride (NaF) rinse; R2: Dentifrice A plus sterile water rinse; R3: Dentifrice B (fluoride-free Dentifrice A) plus sterile water rinse; R4: Dentifrice B plus 450 ppm fluoride (NaF) rinse; R5: Dentifrice C (1000 ppm fluorine as sodium monofluorophosphate, 450 ppm fluoride as NaF) plus sterile water rinse. Subjects wore a palatal appliance holding eight pre-demineralised enamel blocks. A 60 min interval separated in vivo use of dentifrice and rinse with the appliance retained in situ for 4h. Efficacy endpoints were percentage surface microhardness recovery (%SMHR) following remineralisation, and percentage relative erosion resistance (%RER) of recovered specimens following a subsequent in vitro erosive challenge. Statistical analyses included ANOVA and selected twin-tailed t-tests.


RESULTS
Mean %SMHR (±SE) was (a)42.14±1.39, (b)38.02±1.39, (c)30.57±1.39, (b)37.75±1.39 and (c)30.88±1.39 for regimens R1-R5 respectively (different superscripts denote statistically significant differences (p<0.05) between treatment regimens). Mean %RER (±SE) was (a)-2.88±2.16, (b)-14.54±2.16, (c)-40.05±2.16, (a)-3.76±2.16 and (d)-29.48±2.16 for regimens R1-R5 respectively. R1 elicited statistically significantly greater %SMHR versus all comparator regimens (p<0.01), and conferred statistically significantly greater %RER than comparator regimens (p<0.0001) except R4 (p=0.70).


CONCLUSIONS
The combination treatment of dentifrice A containing 1450 ppm fluoride with the 450 ppm fluoride mouthrinse elicited significant enhancements in rehardening of incipient enamel erosive lesions, and significantly increased their subsequent resistance to a second erosive challenge.
GlaxoSmithKline Consumer Healthcare, Parsippany, NJ 07054, USA.
Brenda
B
Maggio
Rita G
RG
Guibert
Stephen C
SC
Mason
Ritu
R
Karwal
Gareth D
GD
Rees
Sue
S
Kelly
Domenick T
DT
Zero
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D003131:Combined Modality Therapy; D018592:Cross-Over Studies; D003743:Dental Enamel / Q000187:drug effects* / Q000648:ultrastructure; D003802:Dentifrices / Q000737:chemistry / Q000627:therapeutic use*; D003807:Dentin Sensitivity / Q000517:prevention & control; D004338:Drug Combinations; D016503:Drug Delivery Systems / Q000379:methods; D005260:Female; D005460:Fluorides, Topical / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009067:Mouthwashes / Q000737:chemistry / Q000627:therapeutic use*; D009566:Nitrates / Q000008:administration & dosage; D017680:Potassium Compounds / Q000008:administration & dosage; D012016:Reference Values; D016037:Single-Blind Method; D018709:Statistics, Nonparametric; D013499:Surface Properties; D014077:Tooth Erosion / Q000517:prevention & control*; D014089:Tooth Remineralization / Q000379:methods*; D055815:Young Adult
D003802:Dentifrices; D004338:Drug Combinations; D005460:Fluorides, Topical; D009067:Mouthwashes; D009566:Nitrates; D017680:Potassium Compounds; C023844:potassium nitrate